Quoin Pharmaceuticals Ltd
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: March 13, 2025 | QUOIN PHARMACEUTICALS LTD. | |
|---|---|---|
| | | |
| | By: | /s/ Dr. Michael Myers |
| | Name: | Dr. Michael Myers |
| | Title: | Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Signature | Title | Date | ||
|---|---|---|---|---|
| | | | | |
| /s/ Dr. Michael Myers | | Chairman and Chief Executive Officer | | March 13, 2025 |
| Dr. Michael Myers | | (Principal Executive Officer) | | |
| | | | | |
| /s/ Gordon Dunn | | Chief Financial Officer | | |
| Gordon Dunn | | (Principal Financial Officer and Principal Accounting Officer) | | March 13, 2025 |
| | | | | |
| /s/ Denise Carter | | | | |
| Denise Carter | | Director and Chief Operating Officer | | March 13, 2025 |
| | | | | |
| /s/ Joseph Cooper | | | | |
| Joseph Cooper | | Director | | March 13, 2025 |
| | | | | |
| /s/ James Culverwell | | | | |
| James Culverwell | | Director | | March 13, 2025 |
| | | | | |
| /s/ Dennis Langer | | | | |
| Dennis Langer | | Director | | March 13, 2025 |
| | | | | |
| /s/ Natalie Leong | | | | |
| Natalie Leong | | Director | | March 13, 2025 |
| | | | | |
| /s/ Michael Sember | | | | |
| Michael Sember | | Director | | March 13, 2025 |
QUOIN PHARMACEUTICALS LTD.
Contents
| | Page |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB Firm ID: Marcum LLP #688) | F-2 |
| Consolidated Financial Statements | |
| Consolidated Balance Sheets as of December 31, 2024 and December 31, 2023 | F-3 |
| Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-6 |
| Notes to consolidated financial statements | F-7 – F-22 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.